

## UK & Ireland National Pilot Programme of Liver Transplantation in Neuroendocrine Patients with Liver Metastases [NET LM]

The NHS Blood and Transplant authority has accepted the guidance of a panel of NET and liver transplant experts to allow liver transplantation for selected NET patients with liver metastases.

The selection of patients for liver transplantation shall initially be based on the criteria defined by the Milan group [Table 1; Ref 1]. The pilot programme shall allow for transplantation in 50 patients over approximately a 5 year period.

Table 1: UK&I selection criteria for liver transplantation in patients with liver metastases from neuroendocrine tumours.

<b>Histology</b>	<b>Grade 1/Grade 2 Well Differentiated NET</b>
<b>Primary Site</b>	<b>Gastro-entero-pancreatic origin</b>
<b>Primary and associated lymphadenopathy</b>	<b>*Resection needs to take place before liver transplantation</b>
<b>Liver metastatic burden</b>	<b>Less than 50% by volume</b>
<b>Disease stability</b>	<b>Stable disease/response to therapies for at least 6 months prior to transplant consideration</b>
<b>Patient age</b>	<b>Less than 60 (relative criteria)</b>

\*patients can be discussed at the national MDT if primary is potentially amenable to complete surgical clearance or already resected.

### Patient Pathway for Liver Transplantation for Neuroendocrine Tumour Liver Metastases

1. NET specialist team identifies potential candidates.
2. Referral to the virtual National MDT [nMDT] using the proforma link: [mdt-tertiary-referral-net-liver-transplant.pdf](https://www.ukinets.org/net-liver-transplantation-pilot-programme-supporting-documents/)
3. Referring team presents the case at the nMDT that takes place on the 4th Thursday of the month 1100-1200.
4. nMDT advises the referring team on eligibility or further steps needed to meet criteria for liver transplantation.
5. Eligible patients will then be referred by the NET teams to their linked liver transplant centres.
6. NET and liver transplant teams shall provide lifelong information on ALL steps for ALL patients' progress to the nMDT.

References: 1. Mazzaferro V, Sposito C, Coppa J, et al. The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. *Am J Transplant* 2016; 16(10): 2892-902.

Delivery documents: <https://www.ukinets.org/net-liver-transplantation-pilot-programme-supporting-documents/>